SecBot SecBot
424B4 ·Filed Nov 19, 2026

MDLN

Medline Inc.
BEARISH
Impact 5/10
Horizonimmediate Processed2d 16h ago SEC0001193125-26-468586
Prospectus supplement
Actionable Insight ▼ Bearish

The large secondary offering by selling stockholders (primarily private equity sponsors Blackstone, Carlyle, H&F, and other pre-IPO investors) signals continued monetization by insiders. The 5.8% discount and 75-day lock-up may create near-term selling pressure. Monitor for any additional secondary filings or insider sales after the lock-up expires.

DirectionBearish
Confidencehigh
Horizonimmediate

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Medline Inc. filed a 424B4 prospectus for a secondary offering of 60 million shares of Class A common stock by selling stockholders at $35.50 per share, totaling $2.13 billion. The company will not receive any proceeds, but will concurrently repurchase $200 million of shares and Common Units from selling stockholders at the underwriter price. The offering represents approximately 6.8% dilution relative to shares outstanding after the repurchase, and the stock is being sold at a 5.8% discount to the $37.68 closing price on November 17, 2026.

Key Financial Metrics

Offering Size
$2.1B
Dilution
6.8%
Lock-up
75 days
Underwriters
Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC +44

Key Facts

  • 60,000,000 shares of Class A common stock offered by selling stockholders at $35.50 per share, total $2.13 billion
  • Public offering price of $35.50 represents a 5.8% discount to the $37.68 closing price on November 17, 2026
  • Underwriters have a 30-day option to purchase up to an additional 9,000,000 shares
  • Company will not receive any proceeds from the offering; all proceeds go to selling stockholders
  • Company and Medline Holdings will repurchase $200 million of shares and Common Units from selling stockholders at $35.05625 per equity interest
  • Class A shares outstanding after offering and repurchase: 895,226,510 (or 898,277,583 if underwriters' option exercised in full)
  • Dilution of approximately 6.8% based on 878,657,055 shares outstanding as of November 2, 2026, after accounting for the repurchase of 3,788,113 shares
  • Underwriting discounts and commissions total $26,625,000 ($0.44375 per share)
  • Lock-up period of 75 days for officers, directors, Principal Stockholders, and Other Pre-IPO Investors
  • Conflicts of interest exist as affiliates of Blackstone and Carlyle own over 10% of outstanding common stock and will receive over 5% of net proceeds; Blackstone Securities Partners L.P. and TCG Capital Markets L.L.C. are underwriters subject to FINRA Rule 5121

Financial Impact

Secondary offering of $2.13 billion at a 5.8% discount to market price, with approximately 6.8% dilution to existing shareholders. Concurrent $200 million repurchase partially offsets dilution but does not change the net dilutive effect.

dilutionshare count

Risk Factors

  • Significant dilution of approximately 6.8% for existing shareholders
  • Selling stockholders are monetizing their positions, indicating potential lack of confidence in near-term upside
  • Concurrent $200 million repurchase only partially offsets the dilutive impact of the offering
  • Designating Stockholders will continue to hold approximately 51.5% voting power after the offering, maintaining concentrated control
  • The company disclosed a voluntary field action and market exit of Medline Brand beds in October 2026, with reports of deaths and serious injuries, which could lead to product liability claims and regulatory action

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
79% bullish (34 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B4 Filing (Primary)0001193125-26-468586
Document: 0001193125-26-468586-index-headers.html0001193125-26-468586
Document: 0001193125-26-468586-index.html0001193125-26-468586
Document: 0001193125-26-468586.txt0001193125-26-468586

Track record

34 reports on MDLN

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +17.95% at T+20 after the May 6, 2026 report. 7 of 10 went positive at some point.

Filters
  1. Nov 19, 20262d ago 424B4 Bearish 5/10 Viewing Entry $39.04 Now $37.04 +5.12% settles Nov 30
  2. Nov 18, 20263d ago 8-K Neutral 4/10 Entry $37.84 Now $37.04 −2.11% settles Nov 27
  3. Nov 18, 20264d ago EFFECT Neutral 5/10 Entry $39.16 Now $37.04 −5.41% settles Nov 25
  4. Nov 17, 20264d ago Press Release Bearish 5/10 Entry $39.16 Now $37.04 +5.41% settles Nov 25
  5. Nov 16, 20266d ago Press Release Bearish 5/10 Entry $39.17 Now $37.04 +5.44% settles Nov 23
  6. Nov 16, 20266d ago S-1 Neutral 4/10 Entry $39.17 Now $37.04 −5.44% settles Nov 23
  7. Nov 13, 20268d ago SC 13G Neutral 3/10 Entry $39.17 Now $37.04 −5.44% settles Nov 23
  8. Nov 13, 20268d ago 144 Neutral 2/10 Entry $39.17 Now $37.04 −5.44% settles Nov 23
  9. Nov 6, 202615d ago SC 13G/A Neutral 3/10 Entry $40.71 to $39.17 Now $37.04 −9.01% ▼ −3.78% −2.09% vs SPY
  10. Nov 4, 202618d ago 8-K Neutral 5/10 No price data
Showing 10 of 34

US Market Status

Market Closed · Opens Mon (25h 11m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 19, 2026